Vaxart, Inc. SEC filings VXRT
Vaxart, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 18, 2011. Its latest annual report, Form ARS, was filed on Jun 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 6, 2026 | — |
| DEFA14A | Additional proxy material | Jul 2, 2026 | — |
| DEFA14A | Additional proxy material | Jul 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 16, 2026 | — |
| DEFA14A | Additional proxy material | Jun 16, 2026 | — |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| DEFA14A | Additional proxy material | May 19, 2026 | — |
| DEFA14A | Additional proxy material | May 19, 2026 | — |
| DEFA14A | Additional proxy material | Sep 8, 2025 | — |
| DEFA14A | Additional proxy material | Aug 21, 2025 | — |
| DEFA14A | Additional proxy material | Aug 15, 2025 | — |
| DEFA14A | Additional proxy material | Aug 8, 2025 | — |
| DEF 14A | Proxy statement | Aug 6, 2025 | Sep 5, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2025 | Sep 5, 2025 |
| DEFA14A | Additional proxy material | May 29, 2025 | — |
| PRE 14A | Preliminary proxy statement | May 29, 2025 | Jun 30, 2025 |
| DEFA14A | Additional proxy material | May 28, 2025 | — |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEF 14A | Proxy statement | Apr 10, 2025 | May 21, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2025 | May 21, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 11, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Jun 21, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 26, 2023 |
| DEFA14A | Additional proxy material | Jul 26, 2022 | — |
| DEFA14A | Additional proxy material | Jul 26, 2022 | — |
| DEFA14A | Additional proxy material | Jul 12, 2022 | — |
| DEFA14A | Additional proxy material | Jul 1, 2022 | — |
| DEFA14A | Additional proxy material | Jul 1, 2022 | — |
| DEFA14A | Additional proxy material | Jun 24, 2022 | — |
| DEFA14A | Additional proxy material | May 25, 2022 | — |
| DEFA14A | Additional proxy material | May 18, 2022 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 7, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 16, 2021 |
| DEFA14A | Additional proxy material | May 15, 2020 | — |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 8, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2020 | Jun 8, 2020 |
| DEFA14A | Additional proxy material | Mar 11, 2019 | — |
| DEF 14A | Proxy statement | Mar 11, 2019 | Apr 23, 2019 |
| PRE 14A | Preliminary proxy statement | Feb 28, 2019 | Apr 23, 2019 |
| DEFA14A | Additional proxy material | Feb 26, 2018 | — |
| DEF 14A | Proxy statement | Feb 26, 2018 | Apr 11, 2018 |
| DEF 14A | Proxy statement | Sep 27, 2016 | Nov 10, 2016 |
| DEF 14A | Proxy statement | Sep 30, 2015 | Nov 10, 2015 |
| DEF 14A | Proxy statement | Oct 3, 2014 | Nov 11, 2014 |
| DEFA14A | Additional proxy material | Nov 5, 2013 | — |
| DEF 14A | Proxy statement | Oct 1, 2013 | Nov 12, 2013 |
| PRE 14A | Preliminary proxy statement | Sep 20, 2013 | Nov 12, 2013 |
| DEFA14A | Additional proxy material | Oct 19, 2012 | — |
| DEFA14A | Additional proxy material | Oct 17, 2012 | — |
| DEFA14A | Additional proxy material | Oct 16, 2012 | — |
| DEFA14A | Additional proxy material | Oct 16, 2012 | — |
| DEFA14A | Additional proxy material | Oct 15, 2012 | — |
| DEFA14A | Additional proxy material | Oct 12, 2012 | — |
| DEFA14A | Additional proxy material | Oct 5, 2012 | — |
| DEFA14A | Additional proxy material | Sep 26, 2012 | — |
| DEFA14A | Additional proxy material | Sep 25, 2012 | — |
| DEFA14A | Additional proxy material | Sep 25, 2012 | — |
| DEFA14A | Additional proxy material | Sep 18, 2012 | — |
| DEFA14A | Additional proxy material | Sep 6, 2012 | — |
| DEFA14A | Additional proxy material | Sep 4, 2012 | — |
| DEFA14A | Additional proxy material | Aug 23, 2012 | — |
| DEFA14A | Additional proxy material | Aug 23, 2012 | — |
| DEFM14A | Definitive notice & proxy statement | Aug 7, 2012 | — |
| DEFA14A | Additional proxy material | Aug 3, 2012 | — |
| DEFA14A | Additional proxy material | Jul 20, 2012 | — |
| DEFA14A | Additional proxy material | Jul 12, 2012 | — |
| DEFA14A | Additional proxy material | Jul 2, 2012 | — |
| DEFA14A | Additional proxy material | Jun 15, 2012 | — |
| PREM14A | Preliminary proxy statement | Jun 8, 2012 | Jun 8, 2012 |
| DEFA14A | Additional proxy material | May 10, 2012 | — |
| DEFA14A | Additional proxy material | May 10, 2012 | — |
| DEFA14A | Additional proxy material | May 1, 2012 | — |
| DEFA14A | Additional proxy material | Apr 26, 2012 | — |
| DEFA14A | Additional proxy material | Apr 25, 2012 | — |
| DEFA14A | Additional proxy material | Apr 24, 2012 | — |
| DEFA14A | Additional proxy material | Apr 23, 2012 | — |
| DEFA14A | Additional proxy material | Apr 23, 2012 | — |
Showing 99 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.